Changes in Hong Kong stocks | Baiosetu-B (02315) rose more than 3%, authorized IDEAYA dual-antibody ADC project IDE034 was approved by FDA IND

The Zhitong Finance App learned that Biosetu-B (02315) rose more than 3%. As of press release, it had risen 2.84% to HK$31.86, and traded HK$12.991,000.

According to the news, according to Baiosetu-B's official WeChat account, on December 5, the company announced that its partner IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a company focusing on the development of precision cancer treatment drugs, has been approved by the US Food and Drug Administration (FDA) for new clinical trials (IND) to advance phase I clinical trials of the first-class B7H3/PTK7 bispecific antibody conjugate (ADC) program. IDEAYA is expected to begin enrolling patients in the first quarter of 2026 to initially evaluate the types of solid tumors where B7H3 and PTK7 are co-expressed, including lung cancer, colorectal cancer, head and neck cancer, and ovarian/gynecological tumors.

According to preclinical studies, IDE034 monotherapy showed deep and long-lasting tumor contraction in various B7H3/PTK7 positive tumor models, showing strong anti-tumor activity. Furthermore, IDEAYA plans to explore combined treatment strategies with IDE034 and its PARG inhibitor IDE161 to enhance the sustainability of efficacy, and plans to share more data supporting the combined treatment mechanism of PARG and TOP1 ADC at key medical conferences in the first half of 2026. The co-expression ratios of B7H3/PTK7 in solid tumors such as lung cancer, colorectal cancer, and head and neck cancer were about 30%, 46%, and 27%, respectively, showing a wide range of potential clinical indications.